Relapse-free survival and overall survival for patients with relapsed or refractory AML with NPM1c by line of therapy. (A) Relapse-free survival following S1. (B) Overall survival following S1. (C) Relapse-free survival following S2. (D) Overall survival following S2. (E) Relapse-free survival following S3+. (F) Overall survival following S3+.